Search

He received six courses of an R-CHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, and two additional doses of rituximab. B Author Information b An event is serious (based on the ICH definition) when the patient outcome is: * death * life-threatening * hospitalisation * disability * congenital anomaly * other medically important event A 56-year-old man exhibited lack of efficacy during treatment with rituximab, gemcitabine, oxaliplatin, cyclophosphamide and prednisone for post-transplant lymphoproliferative disorder (PTLD). He was prescribed bridging therapy with 2 cycles of cyclophosphamide 500 mg/m SP 2 sp day 1 and prednisone 60 mg/m SP 2 sp day 1-5. [Extracted from the article]

He had also been receiving immunosuppressive therapy for kidney transplant consisting of mycophenolate mofetil, which was discontinued at the time of DLBCL diagnosis, tacrolimus was discontinued 2 weeks prior the leukapheresis, and prednisone was continued. Further, they developed cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) during treatment with axicabtagene-ciloleucel for relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). [Extracted from the article]